论文部分内容阅读
目的:探讨大剂量甘露聚糖肽对恶性淋巴瘤患者免疫功能及健康状况的影响。方法:分化疗加甘露聚糖肽组（用药组）和单纯化疗组（对照组）,用药组于化疗同时每日静脉滴注甘露聚糖肽30mg,连续10～14d后检测T淋巴细胞亚群及患者健康状况的变化。结果:用药组化疗后CD3、CD4和 CD56阳性百分率及CD4/CD8比值均明显高于本组化疗前和对照组化疗后水平。用药组患者的健康状况也比本组化疗前和对照组化疗后的健康状况好。结论:大剂量甘露聚糖肽可在短时间内提高淋巴瘤患者机体的免疫功能及健康状况。
Objective: To investigate the effect of high-dose mannan peptide on immune function and health of patients with malignant lymphoma. Methods: The patients in the chemotherapy group were treated with mannan peptide and the chemotherapy alone group (control group). The patients in the chemotherapy group were given 30 mg mannitol peptide daily by chemotherapy and the T lymphocyte subsets And changes in patient health. Results: The positive percentage of CD3, CD4 and CD56 and the ratio of CD4 / CD8 in the treatment group after chemotherapy were significantly higher than those before chemotherapy and in the control group after chemotherapy. The medical condition of the patients in the medication group was also better than that before the chemotherapy and in the control group after chemotherapy. Conclusion: High-dose mannan peptide can improve the immune function and health status of patients with lymphoma in a short period of time.